AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Eligibility Criteria

• * Aged 18 to 80 years old
• * Histologically confirmed relapsed refractory FL (Module 1) and DLBCL (Module 2) after at least 2 prior lines of therapy
• * ECOG performance status 0 to 2
• * Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy
• * FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as \> 1.5 cm in its longest dimension), or extranodal lesion (defined as \> 1.0 cm in its longest dimension)
• * Adequate hematological function: ANC ≥ 1000/mm3, platelets
• * 75,000/mm3, hemoglobin ≥ 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening
• * Adequate liver function: total bilirubin \<1.5x ULN, AST/ALT ≤ 3xULN Note: Patients with documented history of Gilbert's Syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible)
• * Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL/min
• 2. Key
• * Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation
• * Active CNS involvement by B-NHL
• * Leukemic presentation of B-NHL
• * History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
• * Prior therapy with T-cell engager (TCE) within 8 weeks, CAR T- cell therapy or autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, or prior allogeneic HSCT within 24 weeks of first dose of AZD0486
• * Requires chronic immunosuppressive therapy
• * Unresolved non hematological AEs ≥ Grade 2 from prior therapies; history of ≥ Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy
• * History of major cardiac abnormalities.
• * If female, participant must not be pregnant or breastfeeding.